The use of interleukin-2 in human immunodeficiency virus infection.

about

The use of interleukin-2 in human immunodeficiency virus infection.

Item

http://www.wikidata.org/entity/Q36070906

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

The use of interleukin-2 in human immunodeficiency virus infection.

@ast

The use of interleukin-2 in human immunodeficiency virus infection.

@en

type

Item

label

The use of interleukin-2 in human immunodeficiency virus infection.

@ast

The use of interleukin-2 in human immunodeficiency virus infection.

@en

prefLabel

The use of interleukin-2 in human immunodeficiency virus infection.

@ast

The use of interleukin-2 in human immunodeficiency virus infection.

@en

P1476

The use of interleukin-2 in human immunodeficiency virus infection.

@en

P2093

Jaime P Anaya

http://www.w3.org/2001/XMLSchema#string

Jeri J Sias

http://www.w3.org/2001/XMLSchema#string

P2860

Latent reservoirs of HIV: obstacles to the eradication of virus

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection.

Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity.

Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.

Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.

Interleukin-2: inception, impact, and implications.

P304

86-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.25.1.86.55629

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15767224

http://www.w3.org/2001/XMLSchema#string